HUTCHMED announced the retirement of Mr. Christian Hogg after almost 22 years with the Company, including 15 years as Executive Director and Chief Executive Officer and the appointment of Dr. Weiguo Su, who has been with the Company for about 17 years, including about 10 years as Chief Scientific Officer and almost five years as Executive Director, as the new CEO. Dr. Su has been selected and appointed to his additional role as the CEO, as part of the Company's ongoing succession planning. When assuming the new position, Dr. Su will combine the crucial research and development function of the Company for which he has been responsible, with the lead executive role as the CEO.

Prior to HUTCHMED, Dr. Su, aged 64, spent fifteen years in the U.S. Research and Development organization of Pfizer Inc. While Dr. Su will remain as the CSO for the time being, as part of the ongoing succession planning of the Company, Dr. Su, the Nomination Committee and the Board will identify appropriate candidates to take up the leadership of its research and development function. The change to the position of CEO will take effect on March 4, 2022. Also effective from the same date, Mr. Hogg will cease to be a member of the Sustainability Committee and the Technical Committee of the Company.